Albert Cha (’99, ’01)

Albert Cha is a Managing Partner at Vivo Capital, a healthcare focused investment firm.

Albert Cha, M.D., Ph.D. is a Managing Partner who invests in private and public biopharmaceutical and medical device companies. He currently serves on the boards of Ascendis Pharma A/S (NASDAQ: ASND), KalVista Pharmaceuticals (NASDAQ: KALV), and Menlo Therapeutics (NASDAQ: MNLO).

Albert was an investor in Aclaris Therapeutics (NASDAQ: ACRS), Biohaven Pharmaceuticals (NYSE:BHVN), AirXpanders (ASX: AXP), ProNAi Therapeutics (NASDAQ: DNAI), Ceptaris Therapeutics (acquired by Actelion), Neomend (acquired by Bard), Vicept Therapeutics (acquired by Allergan), Bioform Medical (BFRM, acquired by Merz), Biodel (BIOD), and Aspreva Pharmaceuticals (NASDAQ: ASPV, acquired by Galenica). Albert was also involved in founding NextWave Pharmaceuticals (acquired by Pfizer) and Prestwick Pharmaceuticals (acquired by Biovail). Other investments include YM Biosciences (YMI), Dynavax Technologies (DVAX), Avanir Pharmaceuticals (AVNR), Acura Pharmaceuticals (ACUR), and AMAG Pharmaceuticals (AMAG).

"Without the education, mentorship and training I received during my M.D./Ph.D. at UCLA, it would have been impossible for me to be able to launch the career at Vivo," said Albert. "I have been so fortunate through my scientific and medical background from UCLA to help build and invest in great companies during my tenure as a life science investor at Vivo."

When asked why he chose to join UCLA Ventures, Albert said he hoped to strengthen his relationship with UCLA and connect with like-minded alumni who want to be able to give back to the university.

Albert is also a co-founder and board member of the annual Dermatology Summit and Dermatology Innovation Forum. Prior to joining Vivo, Albert worked at Oracle Corporation in pharmaceutical consulting and at the Palo Alto VA Hospital as a biomedical engineer.